Live Quote · NASDAQMRUSHealthcare · Biotechnology

Merus N.V.

$90.00▲ 0.00%(+$0.00)

TickerSpark Score

44/100

▌ Weak

45

Valuation

20

Profitability

10

Growth

84

Health

60

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRUS research report →

52-Week Range89% of range

Low

$33.19

Current

$90.00

High

$97.14

Company Overviewwww.merus.nl

About the company

Merus N. V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies.

CEO: Jan van de Winkel
IPO: 2016
Employees: 260
HQ: Utrecht, NL

Price Chart

+114.03% · this period

Valuation

Market Cap: $6.83B
P/E: -16.85
P/S: 128.91
P/B: 10.29
EV/EBITDA: -20.15
Div Yield: 0.00%

Profitability

Gross Margin: -207.03%
Op Margin: -652.96%
Net Margin: -658.85%
ROE: -50.79%
ROIC: -49.38%

Growth & Income

Revenue: $34.88M · -12.38%
Net Income: $-207,854,187 · -48.10%
EPS: $-3.35 · -11.67%
Op Income: $-262,626,275
FCF YoY: -28.26%

Performance & Tape

52W High: $97.14
52W Low: $33.19
50D MA: $95.61
200D MA: $68.01
Beta: 1.06
Avg Volume: 1.72M

Get TickerSpark's AI analysis on MRUS

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Dec 29, 25	GENMAB A/S	10 percent owner	buy	1,052,806	$102.12M
Dec 26, 25	GENMAB A/S	10 percent owner	buy	2,978	$288.87K
Dec 29, 25	GENMAB A/S	10 percent owner	buy	75,867,199	$7.36B
Dec 26, 25	GENMAB A/S	10 percent owner	buy	142,610	$13.83M
Dec 24, 25	GENMAB A/S	10 percent owner	buy	96,082	$9.32M
Dec 23, 25	GENMAB A/S	10 percent owner	buy	561,042	$54.42M
Dec 22, 25	GENMAB A/S	10 percent owner	buy	15,710	$1.52M
Dec 19, 25	GENMAB A/S	10 percent owner	buy	66,264	$6.43M
Dec 18, 25	GENMAB A/S	10 percent owner	buy	212,177	$20.58M
Dec 17, 25	GENMAB A/S	10 percent owner	buy	150,795	$14.63M

Coverage · MRUS

Our MRUS coverage

Recent articles, reports, and earnings notes.

View all →

Opinion

Abivax’s crash may be the market overpricing a safety scare after a real Phase 3 win

Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.